HRR Mutation Testing in mPC
How might advances in testing for homologous recombination repair (HRR) gene mutations benefit your patients with metastatic castration-resistant prostate cancer (mCRPC)? Over the next 12 months, this Learning Zone will provide resources to help you put these new innovations into practice and identify patients who may be eligible for life-prolonging treatments, including:
- An overview of the prognostic and predictive value of HRR mutations
- Barriers to equitable testing
- Case studies on interpretation of HRR mutation test results
- The patient’s perspective and expert insights to help optimize patient care
- The latest data, with coverage of the ASCO GU, ASCO, and ESMO congresses
Developments in HRR testing in prostate cancer
Find out why HRR status is becoming more valuable for prognosis and treatment decisions
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.
of interest
are looking at
saved
next event